WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Genzyme

GenzymeGenzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme's portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

www.genzyme.com

Genzyme RSS Channel

Filters
List of articles in category Genzyme
Title Published Date
Sanofi Genzyme announces recipients of Patient Advocacy Leadership (PAL) awards 06 January 2016
Genzyme introduces "vs.MS," a global initiative aimed at uncovering the often unspoken challenges of MS to drive better informed care 05 October 2015
Genzyme recognizes World MS Day 30 May 2012
Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients 22 January 2012
Genzyme and Cystic Fibrosis Foundation Therapeutics Announce Collaboration 16 November 2011
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab in Multiple Sclerosis 12 July 2011
Genzyme Celebrates 20th Anniversary of Gaucher Disease Registry with Launch of New Web Platform 17 June 2011
Genzyme Revenues Grow in First-Quarter 2011 29 April 2011
Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease 15 April 2011
Genzyme Board Unanimously Recommends that Shareholders Accept sanofi-aventis Revised Offer and Tender Shares 07 March 2011
Genzyme Recognizes International Rare Disease Day by Launching New Patient Advocacy Grant Program 28 February 2011
Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year 16 February 2011
Genzyme Will Allow sanofi-aventis to Conduct Due Diligence 31 January 2011
Genzyme to Build Additional Plant to Support Growth of Myozyme® and Lumizyme® 20 January 2011
Genzyme Financial Recovery Continues in Fourth Quarter 11 January 2011
Genzyme Statement on Discussions With Sanofi-Aventis 10 January 2011
Genzyme Details Market Potential of Alemtuzumab for MS 20 December 2010
Genzyme Reiterates Board's Position on sanofi-aventis Tender Offer 13 December 2010
Genzyme Completes Sale of Genetic Testing Business to LabCorp 01 December 2010
Genzyme Announces Agreement to Sell Diagnostics Business 18 November 2010
  • Start
  • Prev
  • 1
  • 2
  • 3
  • Next
  • End

Business & Industry

  • GSK completes acquisition of Sierra Oncology
  • Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
  • Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
  • New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
  • Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron

Research & Development

  • Inhalable COVID-19 vaccine shows promise in rodent model
  • Researchers discover new leukemia-killing compounds
  • Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
  • Biomarkers found that could be drug targets against a deadly form of brain cancer
  • COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
  • Novel drug combo activates natural killer cell immunity to destroy cancer cells
  • Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Genzyme

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.